Empowering and equipping Europeans with health information for active personal health management and adherence to treatment
The Gravitate Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsive in their patient journey, specifically encouraging safe use of medicines for better health outcomes and quality of life. It is based on the engagement of citizens in their own health, that, according to the project vision, can only be achieved with access to actionable, understandable, relevant, reliable, and evidence-based information meets their specific needs, health context, and literacy level. The project aims at providing a key piece to advance this vision: the Gravitate Lens (G-Lens), which focuses (but does not conceal or filter) approved electronic product information (ePI) content, and offers a route for patients to access trustworthy, up-to-date information that better meet their individual needs.
Gravitate Health is an integrated digital health information project with two main objectives: 1 –To develop an integrated, digital, user-centric health information solution with two-way communication for the public so that health information from a set of trusted sources is available and understandable (such as package leaflet content) and EHR-IPS (International Patient Summary). 2 - To promote adherence to treatment, safer use of medication (pharmacovigilance), better health outcomes and quality of life through improved availability and understanding of health information from trusted sources & minimize risk through optimal use of available health information. Gravitate Health main outputs will be an open-source digital platform supporting G-Lens functionally, demonstrated in a number of testing scenarios, and a White Paper with recommendations on realistic strategies to strengthen access, understanding and future use of digital services like ePIs as a tool for risk minimization.
The Gravitate Health project is a public – private partnership with 39 members from Europe and the US, funded by the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission, the European Federation of Pharmaceutical Industries and Associations (EFPIA), IMI Associated Partners.
